Levetiracetam: treatment in epilepsy

Bibliography

• PELLOCK JM: Treatment of epilepsy in the new millennium. Pharmacotherapy (2000) 20(8 Pt 2):129S–138S.
   Google Scholar
• BRODIE MJ, FRENCH JA: Role of levetiracetam in the treatment of epilepsy. Epileptic Disord. (2003) 5\(Suppl. 1):S65–S72.
   Google Scholar
• WELTY TE, GIDAL BE, FICKER DM, PRIVITERA MD: Levetiracetam: a different approach to the pharmacotherapy of epilepsy. Ann. Pharmacother: (2002) 36:296–304.
   PubMed Web of Science ®Google Scholar
• KLITGAARD H, PITKANEN A: Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord. (2003) 5:S9–S16.
   Google Scholar
• LOSCHER W, HONACK D: Profile of ucb L059, a novel anticonvulsant drug in models of partial and generalized epilepsy in mice and rats. Eur: Pharmacol (1993) 232:147–158.
   PubMed Web of Science ®Google Scholar
• GOWER AJ, NOYER M, VERLOES R, GOBERT J, WOLFERT E: ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur: Pharmacol (1992) 222:193–203.
   PubMed Web of Science ®Google Scholar
• KLITGAARD H, MATAGNE A, GOBERT J, WOLFERT E: Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. Pharmacol (1998) 353:191–206.
   PubMed Web of Science ®Google Scholar
• FUKS B, GILLARD M, MICHEL P et al.: Localization and photoaffinity labeling of the levetiracetam binding site in rat brain and cell lines. Epilepsia (2002) 43\(Suppl. 7):100.
   Google Scholar
• ANGEHAGEN M, MARGINEANU DG,BEN-MENACHEM E, RONNBOCK L, HANSSON E, KLITGAARD H: Levetiracetam reduces caffeine-induced Ca2' transients and epileptiform potentials in hippocampal neurons. NeuroReport (2003) 14:471–475.
   PubMed Web of Science ®Google Scholar
• KLITGAARD H: Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia (2001) 42:13–18.
   PubMed Web of Science ®Google Scholar
• LOSCHER W, HONACK D,RUNDFELDT C: Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J. Pharmacol Exp. Ther. (1998) 284:474–479.
   PubMed Web of Science ®Google Scholar
• STRATTON SC, LARGE CH, COX B, DAVIES G, HAGAN PM: Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model. Epilepsy Res. (2003) 53:95–106.
   PubMedGoogle Scholar
• HANON E, KLITGAARD H: Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure (2001) 10:287–293.
   PubMed Web of Science ®Google Scholar
• PERUCCA E, JOHANNESSEN SI: The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? Epileptic Disord. (2003) 5\(Suppl. 1):517–526.
   Google Scholar
• PATSAL OS PN: Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. (2000) 83:77–85.
   Google Scholar
• PATSALOS PN: The pharmacokinetic characteristics of levetiracetam. Methods Find. Exp. Clin. Pharmacol (2003) 25:123–129.
   PubMed Web of Science ®Google Scholar
• PERUCCA E, GIDAL BE, BALTES E: Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res. (2003) 53:47–56.
   PubMed Web of Science ®Google Scholar
• COUPEZ R, NICOLAS J-M,BROWNE TR: Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia (2003) 44:171–178.
   PubMed Web of Science ®Google Scholar
• BROWNE TR, SZABO K, LEPPIK E et al: Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique. J. Clin. Pharmacol (2000) 40:590–595.
   PubMed Web of Science ®Google Scholar
• LEVY RH, RAGUENEAU-MAJLESSI I, BALTES E: Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res. (2001) 46:93–99.
   PubMed Web of Science ®Google Scholar
• RAGUENEAU-MAJLESSI I, LEVY RH, JANIK F: Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia (2002) 43:697–702.
   PubMed Web of Science ®Google Scholar
• RAGUENEAU-MAJLESSI I, LEVY RH, MEYERHOFF C: Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res. (2001) 47:53–63.
   Google Scholar
• PERUCCA E, GIDAL BE, LEDENT E, BALTES E: Levetiracetam does not interact with other antiepileptic drugs. Epilepsia (2000) 41:254–255.
   Google Scholar
• DEVINSKY 0, ELGER C: Efficacy of levetiracetam in partial seizures. Epileptic Disord. (2003) 5:S27–S31.
   Google Scholar
• BEN-MENACHEM E, FALTER U: Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. The European Levetiracetam Study Group. Epilepsia (2000) 41:1276–1283.
   PubMed Web of Science ®Google Scholar
• SHORVON SD, LOWENTHAL A, JANZ D, BIELEN E, LOISEAU P: Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. The European Levetiracetam Study Group.Epilepsia (2000) 41:1179–1186.
   PubMed Web of Science ®Google Scholar
• CEREGHINO JJ, BITON V, ABOU-KHALIL B et al.: Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology (2000) 55:236–242.
   PubMed Web of Science ®Google Scholar
• BOON P, CHAUVEL P,POHLMANN-EDEN B, OTOUL C, WROE S: Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. Epilepsy Res. (2002) 48:77–89.
   PubMed Web of Science ®Google Scholar
• SHORVON SD, VAN RUCKEVORSEL: A new antiepileptic drug. Levetiracetam, a pyrrolidone recently licensed as an antiepileptic drug. I Neurol. Neurosurg. Psychiatry (2002) 72:426–429.
   PubMedGoogle Scholar
• ABOU-KHALIL B, LAZENBY B: Long-term experience with levetiracetam. Epileptic Disord. (2003) 5\(Suppl. 1):533–537.
   Google Scholar
• KRAKOW K, WALKER M, OTOUL C, SANDER 'WAS: Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology (2001) 56:1772–1774.
   PubMed Web of Science ®Google Scholar
• BEN-MENACHEM E, EDRICH P, VAN VLEYMEN B, SANDER JWAS, SCHMIDT B: Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res. (2003) 53:57–64.
   PubMed Web of Science ®Google Scholar
• BEN-MENACHEM E, GILLAND E: Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure (2003) 12:131–135.
   PubMed Web of Science ®Google Scholar
• BETTS T, YARROW H, GREENHILL L, BARRETT M: Clinical experience of marketed levetiracetam in an epilepsy clinic - a one year follow up study. Seizure (2003) 12:136–140.
   PubMed Web of Science ®Google Scholar
• MARSON AG, HUTTON JL, LEACH JP et al.: Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res. (2001) 46:259–270.
   PubMed Web of Science ®Google Scholar
• MORRELL MJ, LEPPIK I, FRENCH J,FERRENDELLI J, HAN J, MAGNUS L: The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res. (2003) 54:153–161.
   PubMed Web of Science ®Google Scholar
• DECKERS CLP: Overtreatment in adults with epilepsy. Epilepsy Res. (2002) 52:43–52.
   PubMedGoogle Scholar
• BEN-MENACHEM E: Preliminary efficacy of levetiracetam in monotherapy. Epileptic Disord. (2003) 5\(Suppl. 1):551–555.
   Google Scholar
• ALSAADI TM, THIEMAN C: Levetiracetam monotherapy for newly diagnosed epilepsy patients. Seizure (2003) 12:154–156.
   PubMed Web of Science ®Google Scholar
• KASTELEIJN-NOLST TRENITE DGA, HIRSCH E: Levetiracetam: preliminary efficacy in generalized seizures. Epileptic Disord. (2003) 5\(Suppl. 1):539–544.
   Google Scholar
• KASTELEJN-NOLST TRENITE DGA, MARESCAUX C, STODIECK S, EDELBROEK PM, OOSTING J: Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res. (1996) 25:225–230.
   PubMedGoogle Scholar
• SMITH K, BETTS T, PRITCHETT L: Levetiracetam, a promising option for the treatment of juvenile myoclonic epilepsy. Epilepsia (2000) 41(Suppl.):39.
   Google Scholar
• KRAUSS GL, ABOU-KHALIL B, SHETH SG et al.: Efficacy of levetiracetam for treatment of drug-resistant generalized epilepsy. Epilepsia (2001) 42\(Suppl. 7):181.
   Google Scholar
• PELLOCKJM, APPLETON R: Use of new antiepileptic drugs in the treatment of childhood epilepsy. Epilepsia (1999) 40\(Suppl. 6):529–538.
   Google Scholar
• GLAUSER TA, DULAC 0: Preliminary efficacy of levetiracetam in children. Epileptic Disord (2003) 5\(Suppl. 1):545–550.
   Google Scholar
• GLAUSER TA, PELLOCK JM,BEBIN EM et al.: Efficacy and safety of levetiracetam in children with partialseizures: an open-label trial. Epilepsia (2002) 43:518–524.
   Google Scholar
• LAGAE L, BUYSE G, DECONINCK A, CEULEMANS B: Effect of levetiracetam in refractory childhood epilepsy syndromes. Eur. Pediatr. Neurol. (2003) 7:123–128.
   PubMed Web of Science ®Google Scholar
• FRENCH J, EDRICH P, CRAMER JA: A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res. (2001) 47:77–90.
   PubMed Web of Science ®Google Scholar
• ARROYO S, CRAWFORD P: Safety profile of levetiracetam. Epileptic Disord (2003) 5\(Suppl. 1):557–563.
   Google Scholar
• Keppra® (levetiracetam) tablets. In: Physicians' Desk Reference (57th edn).Medical Economics Co. Inc, Montvale, NJ, USA (2003):3221–3224.
   Google Scholar
• CRAMER J, DE RUE K, DEVINSKY 0, EDRICH P, TRIMBLE MR: A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav. (2003) 4:124–132.
   PubMed Web of Science ®Google Scholar
• BOURGEOIS BFD, HOLDER DL, VALENCIA I et al.: Open-label assessment of levetiracetam efficacy and adverse effects in a pediatric population. Epilepsia (2001) 42\(Suppl. 7):53–54.
   Google Scholar
• NG Y, WHELESS JW: Levetiracetam: pediatric experience. Epilepsia (2001) 42\(Suppl. 7):55–56.
   Google Scholar
• ASCONAPE JJ, GERARDOT JM, DA COSTA G: Behavioral changes associated with levetiracetam use in patients with epilepsy. Epilepsia (2001) 42\(Suppl. 7):299.
   Google Scholar
• VENKATARAMAN A, GUPTA A, MCBRIDE AE, KOLESNIK DV, ETTINGER AB: Adverse psychiatric effects of levetiracetam. Epilepsia (2001) 42\(Suppl. 7):262.
   Google Scholar
• RICKLES NM, GIDAL BE, COLLINS M, HERMANSON MK, SHETH RD, RUTECKI PA: Possible association of behavioral disturbances with levetiracetam: report of a case series. Epilepsia (2001) 42\(Suppl. 7):259–260.
   Google Scholar
• SADEK AH, FIX A, FRENCH J: Levetiracetam-related behavioral adverse events: a post-marketing study. Epilepsia (2002) 43\(Suppl. 8):151.
   Google Scholar
• LEVINSON DF, DEVINSKY 0: Psychiatric adverse events during vigabatrin therapy. Neurology (1999) 53:1503–1511.
   PubMed Web of Science ®Google Scholar
• MULA M, TRIMBLE MR, YUEN A, LIU RS, SANDER JW: Psychiatric adverseevents during levetiracetam therapy.Neurology (2003) 62:704–706.
   Google Scholar
• MULA M, TRIMBLE MR, LHATOO SD, SANDER JW: Topiramate and psychiatric adverse events in patients with epilepsy.Epilepsia (2003) 44:659–663.
   PubMed Web of Science ®Google Scholar
• KRAEMER G, EDRICH P: Levetiracetam in elderly patients with epilepsy.Epilepsia (2001) 42\(Suppl. 7):142–143.
   Google Scholar
• KWAN P, BRODIE MI:Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet (2001) 357:216–222.
   PubMed Web of Science ®Google Scholar
• BERTO P: Quality of life in patients with epilepsy and impact of treatments.Pharmacoeconomics (2002) 20:1039–1059.
   PubMed Web of Science ®Google Scholar
• CRAMER JA, ARRIGO C, VAN HAMMEE G, GAUER LI,CEREGHINO Effect of levetiracetam on epilepsy-related quality of life. The N132 Study Group. Epilepsia (2000) 41:868–874.
   PubMed Web of Science ®Google Scholar
• CRAMER JA, VAN HAMMEE G, N132STUDY GROUP: Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam. Epilepsy Behav. (2003) 4:118–123.
   PubMedGoogle Scholar
• MCCABE PH: New anti-epileptic drugs for the 21st century. Expert Opin. Pharmacother. (2000) 1:633–674.
   PubMedGoogle Scholar
• MELDRUM BS: Concept of activity-induced cell death in epilepsy: historical and contemporary perspectives. Prog. Braila Res. (2002) 135:3–11.
   PubMed Web of Science ®Google Scholar
• CHADWICK D, WOLF P: Meeting thechallenge of treating epilepsy. Epileptic Disord. (2003) 5\(Suppl. 1):57–58.
   Google Scholar
• MELDRUM BS: Implications for neuroprotective treatments. Prog. Braila Res. (2002) 135:487–495.
   PubMedGoogle Scholar
• GAGLIARDI RI: Neuroprotection, excitotoxicity and NMDA antagonists. Arq. Neuropsiquiam. (2000) 58.583–588.
   PubMed Web of Science ®Google Scholar